Anti-β-Gal-hlgG1fut

Non-fucosylated human IgG1 monoclonal antibody against β -galactosidase; Isotype control Catalog # bgal-mab13

http://www.invivogen.com/anti-beta-gal-higg1fut

For research use only, not for diagnostic or therapeutic use

Version # 17F27-MM

PRODUCT INFORMATION

 $\textbf{Content:} \ \ 200 \ \ \mu g \ \ Anti-\beta\text{-}Gal\text{-}hIgG1fut, \ purified \ monoclonal \ antibody,}$

provided azide-free and lyophilized

Specificity: Targets cells expressing *E. coli* β -galactosidase (β -Gal)

Clonality: Monoclonal antibody

Isotype: Human IgG1 Source: CHO cells

Formulation: 0.2 µm filtered solution in sodium phosphate buffer

with glycine, saccharose and stabilizing agents

Purity: Purified by affinity chromatography with protein G

Antibody resuspension

Add 1 ml of sterile water to obtain a concentration of 0.2 mg/ml.

Storage

- Product is shipped at room temperature. Store lyophilized antibody at -20 °C. Lyophilized product is stable for 1 year.
- Reconstituted antibody is stable for 1 month when stored at 4 $^{\circ}$ C and for 1 year when aliquoted and stored at -20 $^{\circ}$ C. Avoid repeated freeze-thaw cycles.

Quality control

- Absence of binding of Anti-β-Gal-hIgG1fut to human cell lines has been tested using flow cytometry.
- The complete sequence of this antibody has been verified.
- The absence of bacterial contamination, lipoproteins and endotoxins, has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

DESCRIPTION

Anti- β -Gal-hIgG1fut features the constant region of the human IgG1 isotype and the variable region of Mouse IgG2a Control. Mouse IgG2a Control is a mouse IgG2a monoclonal antibody that targets $E.\ coli\ \beta$ -galactosidase (β -Gal). This antibody was generated by DNA immunization with a plasmid expressing the β -Gal gene in Swiss mice. Anti- β -Gal-hIgG1fut is a non-fucosylated antibody. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC) without any detectable change in complement-dependent cytotoxicity (CDC) or antigen binding capability. Anti- β -Gal-hIgG1fut can be used as an isotype control for human IgG1fut antibodies. Anti- β -Gal-hIgG1fut was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography.

1. Yamane-Ohnuki N. & Satoh M., 2009. Production of therapeutic antibodies with controlled fucosylation.corresponding MAbs. 1(3): 230–236. 2. Mizushima T., 2011. Structural basisfor improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells. 16(11): 1071–1080.

ANTIBODY ISOTYPE FAMILY

For your research, InvivoGen provides an anti-β-Gal isotype family. This family consists of monoclonal antibodies comprising the variable region of a mouse monoclonal antibody targeting *E. coli* β-galactosidase (β-Gal), named mouse IgG2a control, and the constant region of three different human isotypes; IgG1, IgG4 and IgA2. The isotypes differ in their functional locations and effector functions, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), as presented in the table below.

Isotype	Description
Human IgG1	Most abundant IgG present in serum High CDC, high ADCC
Human IgG4	Least common IgG present in serum No CDC, low ADCC
Human IgA2	Major class in secretions, oligomeric forms, highly resistant to enzymatic degradation. No CDC, low ADCC

RELATED PRODUCTS

Product	Catalog Code
Anti-β-Gal-hIgG1	bgal-mab1
Anti-β-Gal-hIgG4	bgal-mab4
Anti-β-Gal-hIgG4 (S228P)	bgal-mab114
Anti-β-Gal-hIgA2	hbgal-mab7
Mouse IgG2a Control	mabg2a-ctrlm

Several antibody isotype families are available, such as Anti-hCD20, Anti-HER2 and Anti-hPD1.

For more information visit www.invivogen.com/antibody-isotypes

